Table 3. Plasma and Fecal Phospholipids in Placebo and LXS Groups at Baseline and 3 Months.
| Variable | n | Baseline | n | 3 Months | P1 | P2 |
|---|---|---|---|---|---|---|
| Plasma Fat Soluble Phospholipids, μmol/L | ||||||
|
| ||||||
| LPC | ||||||
| Placebo | 56 | 168 ± 70 | 46 | 175 ± 79 | 0.371 | 0.274 |
| LXS | 51 | 165 ± 59 | 40 | 180 ± 65† | 0.026 | |
| PC | ||||||
| Placebo | 56 | 1915 ± 457 | 46 | 1978 ± 513 | 0.244 | 0.979 |
| LXS | 51 | 1882 ± 449 | 40 | 1979 ± 422 | 0.272 | |
| SM | ||||||
| Placebo | 56 | 325 ± 120 | 46 | 330 ± 124 | 0.318 | 0.037 |
| LXS | 51 | 356 ± 155 | 40 | 334 ± 139 | 0.064 | |
| LPE | ||||||
| Placebo | 56 | 42 (18 - 100) | 46 | 39 (19 - 78) | 0.942 | 0.068 |
| LXS | 51 | 39 (17 - 71) | 40 | 45 (19 - 71)†† | 0.001 | |
| PE | ||||||
| Placebo | 56 | 421 (179 - 973) | 46 | 397 (248 - 1253) | 0.516 | 0.220 |
| LXS | 51 | 415 (209 - 857) | 40 | 470 (211 - 1144)† | 0.023 | |
| PC/PE Ratio | ||||||
| Placebo | 56 | 4.48 (1.48 - 9.72) | 46 | 4.42 (1.81 - 8.12) | 0.907 | 0.198 |
| LXS | 51 | 4.44 (0.77 - 10.5) | 40 | 3.90 (1.58 - 9.94)† | 0.019 | |
|
| ||||||
| Fecal Phospholipids, μg/g stool | ||||||
|
| ||||||
| LPC | ||||||
| Placebo‡ | 52 | 52 (1 - 259) | 37 | 37 (0 - 575) | 0.724 | 0.260 |
| LXS | 44 | 65 (2 - 1271) | 30 | 53 (3 - 565) | 0.356 | |
| PC | ||||||
| Placebo | 52 | 107 (0 - 1096) | 37 | 73 (4 - 946) | 0.901 | 0.074 |
| LXS | 44 | 212 (2 - 1609) | 30 | 118 (4 - 1293) | 0.035 | |
| SM | ||||||
| Placebo | 52 | 14 (0 - 176) | 37 | 14 (0 - 89) | 0.277 | 0.691 |
| LXS | 44 | 22 (1 - 113) | 30 | 18 (0 - 178) | 0.854 | |
| PE | ||||||
| Placebo | 52 | 64 (13 - 242) | 37 | 58 (9 - 326) | 0.909 | 0.308 |
| LXS | 44 | 82 (9 - 425) | 30 | 69 (16 - 238) | 0.190 | |
| PC/PE Ratio | ||||||
| Placebo | 52 | 1.33 (0.00 - 4.51) | 37 | 0.90 (0.06 - 6.21) | 0.645 | 0.062 |
| LXS | 44 | 2.12 (0.05 - 10.6)* | 30 | 1.16 (0.10 - 5.97)†† | 0.002 | |
Definitions: LPC, lysophosphatidylcholine; PC, phosphatidylcholine; SM, sphingomyelin; LPE, lysophosphatidylethanolamine; PE, phosphatidylethanolamine.
Data are presented as mean ± SD for normally distributed and median (minimum - maximum) for skewed data
P1 is testing for Time effect within the randomization groups; P2 is testing for Randomized by Time interaction effect.
3-mo value significantly different from baseline within randomization group , p<0.05,
p<0.01
Randomization groups significantly different within visit by student’s unpaired t-test or Wilcoxon rank sum test for continuous variables and chi-square test or Fisher’s exact test for categorical variables, p<0.05,
p<0.01
One subject randomized to the placebo group was removed from the analyses of fecal phospholipids as an extreme outlier in loss of phospholipids.